INCY vs WLYB · P/E 14, rev $5.14B vs P/E 15, rev $1.68B
Incyte Corporation (INCY) versus John Wiley & Sons B (WLYB) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
John Wiley & Sons B (WLYB) is a publishing company listed on NYSE.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported WLYB revenue for 2026-04-30 was $1.68B. Net income was $221.6M. Revenue was down 0.1% from 2025-04-30 to 2026-04-30. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
Not investment advice. Open the INCY and WLYB stock pages for the full models.
Not investment advice.